Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE. IMCIVREE is a precision medicine approved by the FDA for chronic weight management in adults and children aged six and older with monogenic or syndromic obesity due to POMC, PCSK1, or LEPR deficiencies, or Bardet-Biedl syndrome (BBS). The company is also evaluating setmelanotide in Phase II and III trials for treating obesity linked to various MC4R pathway gene variants. We show 32 historical shares outstanding datapoints in our RYTM shares outstanding history coverage, used to compute RYTM market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing RYTM market cap history over the course of time is important for investors
interested in comparing RYTM's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of RYTM versus a peer is one thing; comparing
RYTM market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like RYTM can fluctuate over the course of history.
With this page we aim to empower investors researching RYTM by allowing them to research the RYTM market cap history. |
Free RYTM Email Alerts:
Video: The Importance of Market Cap
